Abstract: The present invention relates to novel benzotriazoles and to novel topical compositions comprising these benzotriazoles. Furthermore, the invention relates to the use of the novel benzotriazoles as photostabilizer and solubiliser for dibenzoyl-methane derivatives such as Butyl Methoxydibenzoylmethane. In one aspect the invention relates to novel benzotriazoles of formula (Ia) wherein R2 is hydrogen; C1-30alkyl; C1-5alkoxy; C1-5alkoxycarbonyl; C5-7cycloalkyl; C6-10aryl or aralkyl; R3 is hydrogen; C1-5alkyl; C1-5alkoxy or halogen, preferably hydrogen or Cl; R4 is hydrogen or C1-5alkyl; R5 is C1-30alkyl or C5-10cycloalkyl.

Abstract: In some example embodiments, there is provided a method for sunless tanning. The method may include applying a sunless tanning solution to the skin and applying, during a drying stage of the sunless tanning solution, a powder to at least dry the tanning solution. Related compounds and methods may also be disclosed.

Abstract: A method for synthesizing an isothiocyanate of general formula (I) SCN—R1—R4—R2??(I) wherein R1 and R2 represent independently of each other an alkyl-aryl or aryl group, R4 represents a carbonyl, sulfinyl, sulfonyl group or a sulfide group and of its derivatives comprising a step for reacting an alkylalkylamine having the general formula (II) NH2—R1—R4—R2??(II) wherein R1 and R2 represent independently of each other an alkyl, aryl or alkylaryl group, R4 represents a carbonyl, sulfinyl, sulfonyl or sulfide group, in the presence of carbon sulfide and of di-tert-butyl dicarbonate with formation of the corresponding aforesaid isothiocyanate, compounds obtained by this method as well as their uses.

Abstract: The present invention is directed to a sunscreen composition containing a novel preservative system for inhibiting micro-organisms comprising (a) at least one aromatic carboxylic acid, or salt thereof; (b) from about 0.01% to about 1% by weight of at least one at least one aromatic alcohol; (c) at least one sunscreen active; and (d) a cosmetically acceptable carrier.

Abstract: A composition for external use containing a tranexamate as an active ingredient with suppressed sticky or oily feeling but having a fresh feel of use, and a method for producing the same. A tranexamate salt can be dispersed stably in an aqueous medium by (a) dissolving the tranexamate salt and an amphiphilic polymer in water, a water-soluble organic solvent or a mixture thereof; and (b) adding a mixed solution obtained in the step (a) to an aqueous medium, and thus keeping the tranexamate salt in molecular assembly particles formed of the amphiphilic polymer.

Abstract: The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition.

Abstract: A cosmetic process for making up and/or caring for skin and/or lips, includes the application to skin and/or lips of a cosmetic composition including, in a physiologically acceptable medium, at least one supramolecular polymer and at least one hydrophobic film-forming polymer. Particular compositions may be used in the process.

Abstract: A method of producing a lip cosmetic, comprising the steps of: (i) mixing an oligomer (ingredient (a)) produced from behenic acid, eicosane diacid, and a glycerin condensate, a polyol (ingredient (b)), and water (ingredient (c)) to prepare a solution containing ingredients (a), (b), and (c); (ii) mixing an ester oil (ingredient (d)) composed of a carboxylic acid having 2 to 36 carbon atoms and an alcohol having 1 to 36 carbon atoms, being in a liquid or paste form at ordinary temperature, and having a viscosity of 300 mPa·s or more at 25° C. and an oligomer (ingredient (e)) produced from behenic acid, eicosane diacid, and glycerin to prepare a solution containing ingredients (d) and (e); and (iii) mixing the solution containing the ingredients (a), (b), and (c) and the solution containing the ingredients (d) and (e).

Abstract: A cosmetic composition particularly intended to be cast into a cup with view to a use as a lip gloss, contains: (a) at least one glossy oil; (b) at least one ester obtained from: (i) a saturated or unsaturated, linear or branched aliphatic acid or hydroxy acid, having from 8 to 30 carbon atoms, (ii) a linear or branched diacid having from 12 to 36 carbon atoms, and (iii) glycerol or a glycerol condensate; (c) at least one hydrophobicized pyrogenated silica; (d) at least one wax consisting of a homo- or co-polymer of ethylene; and (e) optionally stearic acid. The lip gloss, and a lip care or make-up cosmetic method including the topical application of this composition on the lips are also described.

Abstract: An aerated hair styling gel delivery system comprises a hair styling gel with entrained air stably packaged in and delivered from a bag-on-valve dispensing package. The hair gel remains lighter in density than hair styling gels packaged in conventional plastic cosmetic tubes or tubs.

Abstract: The invention relates to a composition containing between 0.1 and 30 wt.-% copolyamide (COPA) and between 70 and 99.9 wt.-% of a medium acceptable for cosmetic, perfume and/or pharmaceutical use. In particular, the invention relates to a method for incorporating a copolyamide into a cosmetic, perfume and/or pharmaceutical medium. The invention also relates to the use of a copolyamide (COPA) for the production of a cosmetic, pharmaceutical or perfume product, said COPA being incorporated in the form of a composition in accordance with the invention.

Abstract: The present invention provides a cosmetic for hair in which smooth combability without a frictional sensation during cleansing and applying to hair, namely during wetting, the aforementioned effects are not lost by a rinsing operation, smooth combability during and after drying the hair is exhibited, a moisturizing feeling on touch is exhibited without stickiness, and a flexible styling sensation is provided to the hair. A co-modified organopolysiloxane having both a specified hydrophilic group and a siloxane dendron structure-containing group is blended in a cosmetic for hair as an essential component.

Abstract: A method of straightening hair comprising the steps of applying to the hair on at least two successive occasions a composition comprising a titanium complex selected from the group consisting of citrate, oxalate and tartrate or the metal alkali salt of these. The complex is preferably titanium citrate or sodium titanium citrate. The composition may further comprise a silicone.

Abstract: Compositions and methods are disclosed for imparting a long-wearing shine to keratin fibers, including hair. The compositions comprise an aminosilicone polymer having a viscosity from about 800 to about 1,600 mm2/s at 25° C., and a functional group equivalent weight from about 8,000 to about 14,000 g/mol. The compositions comprise an aminosilicone polymer and optionally a shine enhancer. The compositions are useful for imparting a long-wearing shine to hair.

Abstract: A colored, sodium bicarbonate-based, composition that is, for example, a fabric freshener and deodorizer that can be colored with non-toxic ingredients is provided. A colored baking soda composition may be used to suppress malodor, for freshening fabrics comprising sodium bicarbonate, a coloring agent and a method of use thereof comprising applying the composition uniformly to the fabric and thereafter blending into fabric to remove unwanted odor. The colored baking soda is produced by mixing same together then, in one step, the mixture of the two components undergoes simultaneous mixing-refining until the desired color is obtained. The quantities of colors will vary, the amount of coloring matter used depends upon the depth of shade it is desired to produce, colors can be toned with additional baking soda. A baking soda-based product used to remove malodor, that can be colored with non-toxic ingredients is provided.

Abstract: The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.

Abstract: Disclosed and claimed herein is a device and method for generating carbon dioxide as an attractant for biting arthropods in combination with a trap, comprising: a reaction chamber charged with an aqueous acid solution when in use; a gas outlet from the reaction chamber connecting between the reaction chamber and the trap; a feeder reservoir containing a powder when in use, said powder comprising a bicarbonate salt; and means for controllably adding the powder to the reaction chamber; whereby carbon dioxide is generated in the reaction chamber, passed through the outlet and into the trap.

Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: A method for increasing a biological activity of a cytokine or lymphokine and a method of treating a neoplastic disease, autoimmune disease, or infectious disease, and a method for expanding a hematopoietic cell population, is provided by administering an antibody capable of binding a cytokine or by administering a cytokine complexed with an antibody or by administering a cytokine complexed with a cytokine receptor to a mammalian subject in need thereof.

Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.

Abstract: Disclosed are compounds of general formula (I), wherein R, R1, Rc, Rd, Re, Rf, X, Y, Z, A and B are as defined in the application.

Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Abstract: A method for controlling nematodes in or on a plant, a plant part, and/or a locus for plant growth is provided, the method comprising applying to a plant, plant part, or locus for plant growth in need of protection from said nematodes an effective amount of Bacillus pumilus, a mutant of Bacillus pumilus, or at least one metabolite of Bacillus pumilus. In particular, the Bacillus pumilus strain may be strain QST2808.

Abstract: A method of changing the phenotype of monocytes and macrophages from a pro inflammatory MI phenotype to an anti-inflammatory M2 phenotype is disclosed. The method can comprises providing a composition comprising a recombinant adeno-associated virus (rAAV) vector comprising an exogenous gene encoding ApoA-1 Milano or a fragment thereof, and administering the composition to mammal in need thereof to change the phenotype of monocytes or macrophages from a pro inflammatory M1 phenotype to an anti inflammatory M2 phenotype. By changing the phenotype of monocytes or macrophages from a pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, atherosclerosis can be treated. A method of monitoring macrophage phenotypic switching and a method of assessing the efficacy of the treatment of atherosclerosis are also described.

Abstract: The invention relates to a method for enhancing the transplantation of hematopoietic cells to supplement or fully reconstitute the hematopoietic system. The method involves administering cells expressing CD34 and co-expressing HoxB4, wherein the HoxB4 is expressed at levels that provide therapeutically effective amounts of self-renewal of the administered cells. The method also involves administering cells expressing CD34 but not co-expressing HoxB4 or co-expressing HoxB4 in amounts so as to provide therapeutically effective amounts of differentiation of the administered cells into the various progeny cells of the hematopoietic system. To provide such cells to a subject, the invention relates to detecting such cells prior to treatment to ascertain whether such cells are present in clinically relevant amounts.

Abstract: Provided herein is a new method to isolate and expand cardiac progenitor/stem cells from a placenta, which produces a cell population enriched in multipotent functional progenitor/stem cells. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. Also provided in this application are substantially pure populations of multipotent cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction. A model for assessing the potential of cardiac stem cells for treatment of myocardial infarction is also provided.

Abstract: Crosslinked cellulosic polymers, crosslinked cellulosic polymer hydro-gels, and methods for their synthesis and use are described. The crosslinked cellulosic polymers include one or more cellulosic polymers and a one or more crosslinkers that crosslinks the one or more cellulosic polymers together. The crosslinking can be facilitated with a crosslinking agent capable of linking with a monomer the cellulosic polymer and crosslinking the cellulosic polymer intermoleculerly and/or intramolecularly. Crosslinked cellulosic polymers are well adapted for use in cell and tissue growth in vivo and in vitro. The crosslinked cellulose polymers may also be used as wound care devices.

Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.

Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.

Abstract: The present invention addresses the problem of providing cell populations having a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, and a production method thereof. The present invention provides a production method for CD4-positive T cell populations which is characterized by using anti-CD3 antibodies, fibronectin fragments, and Interleukin-4. The method is characterized not only by the attainment of a cell group with a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, but also by a high bulk yield.

Abstract: The present invention relates to a method of producing reduced coenzyme Q10, including reducing oxidized coenzyme Q10 using a reducing agent in terpenes that can highly dissolve oxidized coenzyme Q10 and reduced coenzyme Q10 in the co-existence of at least one kind of additive selected from the group consisting of alcohols, water, a surfactant and diacylglycerol. In addition, the present invention relates to a composition comprising terpenes, a reducing agent, reduced coenzyme Q10 and at least one kind selected from the group consisting of alcohols, water, a surfactant and diacylglycerol, and a method of stabilizing reduced coenzyme Q10 comprising preparing the composition.

Abstract: The present invention relates to a method for promoting eye health by administering to a companion animal a composition comprising at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures thereof.

Abstract: The invention relates to treatments of cognitive disorders e.g. Mild Cognitive Disorder comprising the use of agents which are capable of lowering homocysteine levels in a subject, preferably a human subject. Aspects of the invention relate to a method of treating such disorders comprising administering one or more B vitamins e.g. folic acid, Vitamin B6 and/or Vitamin B12 or derivatives thereof.

Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, and cholecystitis for example.

Abstract: A hydrolytic enzyme is stabilized in a liquid surfactant preparation using a component that stabilizes the hydrolytic enzyme and encompasses an oligoaminobiphenyl oligocarboxylic acid.

Abstract: A hydrolytic enzyme is stabilized in a liquid surfactant preparation using a component that stabilizes the hydrolytic enzyme and includes a phenylalkyldicarboxylic acid.

Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.

Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.

Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.

Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.

Abstract: The invention relates to the field of medicaments for combating an infection of a host cell by HI viruses and/or for inhibiting binding of an Env protein to a CD4 protein. For these purposes, the invention provides medicaments which comprise oxidized proteins, oxidized peptides and/or peptidomimetics of such oxidized proteins and/or oxidized peptides, as well as preparation processes for such medicaments and therapeutic and non-therapeutic possible uses of these medicaments.

Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.

Abstract: Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.

Abstract: The invention relates to aerosolized and humidified particles comprising a therapeutically active substance which can be obtained by suspending dry inhalable particles in a carrier gas, adding water vapor and causing condensation of water on the particles. The invention further relates to methods to generate these particles, and apparatus useful to carry out such methods.

Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Abstract: The invention provides methods of treating cancer, especially breast cancer, and in particular HER2/ErbB2 positive breast cancer using a FoxM1 inhibitor in conjunction with trastuzumab and/or paclitaxel. Pharmaceutical compositions comprising a FoxM1 inhibitor in the presence of trastuzumab and/or paclitaxel are also provided. The invention further provides methods of identifying and treating trastuzumab resistant and/or paclitaxel resistant cancer. Also provided are methods of promoting breast tumor cell differentiation.

Abstract: The present invention relates to compositions, methods, and kits for treating cancers with HER2 targeting agents and preventing resistance thereto. In particular embodiments, non-HER2-amplified cancers are treated with HER2 targeting agents, wherein the cancer stem cells in the cancer express HER2 and/or HER2 indicator marker. The present invention also relates to compositions, methods, and kits for detecting expression of HER2 and/or a HER2 indicator marker in non-HER2-amplified cancer samples from a subject, and identifying the subject as responsive to treatment with a HER2 targeting agent and/or treating the subject with a HER2 targeting agent.

Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.